{Reference Type}: Journal Article
{Title}: Risk-Based Therapeutic Strategies for HER2-Positive Early Breast Cancer: A Consensus Paper.
{Author}: Garutti M;Cucciniello L;Arpino G;Fabi A;Livi L;Munzone E;Staropoli N;Zamagni C;Zambelli A;Puglisi F;
{Journal}: Clin Breast Cancer
{Volume}: 23
{Issue}: 7
{Year}: 2023 Oct 26
{Factor}: 3.078
{DOI}: 10.1016/j.clbc.2023.07.006
{Abstract}: Breast cancer represents the most commonly diagnosed neoplasm worldwide and the HER2-positive subtype accounts for nearly 1 in 5 breast cancers. The majority of patients with breast cancer present with an early-stage disease upon diagnosis, which is thus susceptible to virtually curative treatment strategies. For a stage, I T1a/b N0 HER2-positive disease, upfront surgery followed by adjuvant therapy is the preferred approach. However, there is some uncertainty regarding the appropriate management of stage cT1c cN0, as both the neoadjuvant approach and upfront surgery have been proven to be feasible therapeutic options. The aim of this Delphi consensus was to define the best strategies for the treatment of early HER2-positive breast cancer. This work may help clinicians in the management of early HER2-positive breast cancer.